AIM: To investigate the survival rates and prognostic factors in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). METHODS: Clinical data in hospitalized patients with HBV-ACLF admitted from 2006 to 2009 were retrospectively analyzed. Their general conditions and survival were analyzed by survival analysis and Cox regression analysis. RESULTS: A total of 190 patients were included in this study. The overall 1-year survival rate was 57.6%. Patients not treated with antiviral drugs had a significantly higher mortality [relative risk (RR) = 0.609, P = 0.014]. The highest risk of death in patients with ACLF was associated with hepatorenal syndrome (HRS) (RR = 2.084, P =0.026), while other significant factors were electrolyte disturbances (RR = 2.062, P = 0.010), and hepatic encephalopathy (HE) (RR = 1.879, P < 0.001). CONCLUSION: Antiviral therapy has a strong effect on the prognosis of the patients with HBV-ACLF by improving their 1-year survival rate. HRS, electrolyte disturbances, and HE also affect patient survival.
AIM: To investigate the survival rates and prognostic factors in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). METHODS: Clinical data in hospitalized patients with HBV-ACLF admitted from 2006 to 2009 were retrospectively analyzed. Their general conditions and survival were analyzed by survival analysis and Cox regression analysis. RESULTS: A total of 190 patients were included in this study. The overall 1-year survival rate was 57.6%. Patients not treated with antiviral drugs had a significantly higher mortality [relative risk (RR) = 0.609, P = 0.014]. The highest risk of death in patients with ACLF was associated with hepatorenal syndrome (HRS) (RR = 2.084, P =0.026), while other significant factors were electrolyte disturbances (RR = 2.062, P = 0.010), and hepatic encephalopathy (HE) (RR = 1.879, P < 0.001). CONCLUSION: Antiviral therapy has a strong effect on the prognosis of the patients with HBV-ACLF by improving their 1-year survival rate. HRS, electrolyte disturbances, and HE also affect patient survival.
Authors: Kiran Bambha; W Ray Kim; Walter K Kremers; Terry M Therneau; Patrick S Kamath; Russell Wiesner; Charles B Rosen; Jeff Thostenson; Joanne T Benson; E Rolland Dickson Journal: Am J Transplant Date: 2004-11 Impact factor: 8.086
Authors: A Tsubota; Y Arase; S Saitoh; M Kobayashi; Y Suzuki; F Suzuki; K Chayama; N Murashima; K Ikeda; M Kobayashi; H Kumada Journal: Am J Gastroenterol Date: 2001-02 Impact factor: 10.864
Authors: Anna Rutherford; Tim Davern; J Eileen Hay; Natalie G Murray; Tarek Hassanein; William M Lee; Raymond T Chung Journal: Clin Gastroenterol Hepatol Date: 2006-09-25 Impact factor: 11.382
Authors: H L Tillmann; J Hadem; L Leifeld; K Zachou; A Canbay; C Eisenbach; I Graziadei; J Encke; H Schmidt; W Vogel; A Schneider; U Spengler; G Gerken; G N Dalekos; H Wedemeyer; M P Manns Journal: J Viral Hepat Date: 2006-04 Impact factor: 3.728
Authors: Sara Blasco-Algora; José Masegosa-Ataz; María Luisa Gutiérrez-García; Sonia Alonso-López; Conrado M Fernández-Rodríguez Journal: World J Gastroenterol Date: 2015-11-14 Impact factor: 5.742